Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | THRB | P10828 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.74 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889532 | 1.00 | CNR2 (0.74) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL5145799 | 0.95 | ALDH1A1 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL11872018 | 0.95 | ALDH1A1 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL5682652 | 0.95 | ALDH1A1 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL653624 | 0.95 | ALDH1A1 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL2225404 | 0.90 | ASAH2 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL6846748 | 0.90 | ASAH2 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL9109309 | 0.90 | ASAH2 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL1147692 | 0.90 | ASAH2 (0.68) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB | |
| SCHEMBL6534948 | 0.89 | CNR2 (0.76) | CNR2SMN1; SMN2KCNK3ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 581 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713314-A1 | A BINDING SITE TO PREVENT ENDOCANNABINOID CELLULAR REUPTAKE | Universität Bern (CH) | 2026-03-25 | — | — | EP | claimed |
| US-12178904-B2 | Contact lenses including medicaments and methods of making and using same including stabilizers of labile components such as drugs | MEDIPRINT OPHTHALMICS INC. | 2024-12-31 | — | — | US | claimed |
| WO-2024240779-A1 | A BINDING SITE TO PREVENT ENDOCANNABINOID CELLULAR REUPTAKE | Universität Bern (CH) | 2024-11-28 | — | — | WO | claimed |
| EP-4041748-B1 | PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS | UNIV BARCELONA (ES) | 2024-05-01 | — | — | EP | claimed |
| US-11752115-B2 | PPAR-alpha agonist treatment of neuropsychiatric disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-09-12 | — | — | US | claimed |
| US-20220370650-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | VYRIPHARM ENTERPRISES, INC. | 2022-11-24 | — | — | US | claimed |
| WO-2022204421-A1 | NATURAL CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| WO-2022204414-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| US-20220305148-A1 | NATURAL CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. | 2022-09-29 | — | — | US | claimed |
| EP-3800195-A1 | PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS | Universitat de Barcelona (ES) | 2021-04-07 | — | — | EP | claimed |
| US-20170252469-A9 | Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression | THE UNITED OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2017-09-07 | — | — | US | claimed |
| US-20150374857-A1 | Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression | SCHULTZ STEPHEN T (US) | 2015-12-31 | — | — | US | claimed |
| US-20120225015-A1 | Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression | UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2012-09-06 | — | — | US | claimed |
| EP-1383537-B1 | NOVEL CHOCOLATE COMPOSITION AS DELIVERY SYSTEM FOR NUTRIENTS AND MEDICATIONS | ALTAFFER PAULO (US) | 2006-06-07 | — | — | EP | claimed |
| US-7048941-B2 | Chocolate composition as delivery system for nutrients and medications | NEW WORLD ENTERPRIZES, INC. (US) | 2006-05-23 | — | — | US | claimed |
| EP-1383537-A4 | NOVEL CHOCOLATE COMPOSITION AS DELIVERY SYSTEM FOR NUTRIENTS AND MEDICATIONS | ALTAFFER PAULO (US) | 2005-09-14 | — | — | EP | claimed |
| EP-1383537-A1 | NOVEL CHOCOLATE COMPOSITION AS DELIVERY SYSTEM FOR NUTRIENTS AND MEDICATIONS | Altaffer, Paulo (US) | 2004-01-28 | — | — | EP | claimed |
| US-20020192316-A1 | Novel chocolate composition as delivery system for nutrients and medications | NEW WORLD ENTERPRIZES, INC. | 2002-12-19 | — | — | US | claimed |
| WO-2002078746-A1 | NOVEL CHOCOLATE COMPOSITION AS DELIVERY SYSTEM FOR NUTRIENTS AND MEDICATIONS | ALTAFFER, PAULO (US) | 2002-10-10 | — | — | WO | claimed |
| EP-0122151-B1 | PRODUCTION OF PRIMARY OR SECONDARY ALCOHOL DERIVATIVES OF PHOSPHOLIPIDS BY THE ENZYMATIC TECHNIQUE | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1989-02-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220305148-A1 | NATURAL CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | CNR2, CNR1, FAAH | CNR2 1/4885SMN1; SMN2 1422/4885KCNK3 2484/4885 |
| US-20220370650-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | ADA, SLC29A1, SLC29A2 | CNR2 4580/4885SMN1; SMN2 678/4885KCNK3 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.